Siqing Fu, MD & Razelle Kurzrock, MD
MD Anderson Cancer Center, Houston, TX
Clinical Title: Phase I Study of Surface-Controlled Water Soluble Curcumin in Patients with Advanced Malignancies
Description: The goal of this clinical research study is to find the highest tolerable doses of surface-controlled water dispersible curcumin that can be given to patients with advanced cancer. The safety of this drug will also be studied.
Curcumin is well known for its anticancer activities in cancer cells; however, broad clinical implementation has been limited due to poor oral absorption, rapid metabolism and expeditious systemic elimination. This study tests a novel nanotechnology-enhanced curcumine compound dispersed with colloidal nano-particles, which enhances bioavailability thirty fold.
Status: Active Trial
Accepting Patients? No
NIH Clinical Trial Link: http://www.clinicaltrials.gov/ct2/show/NCT01201694?term=curcumin+and+MD+Anderson&rank=1« Back to Funded Clinical Trials
1,500 American people died today from cancer.
1,500 more will die tomorrow and the next day and the next...
Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.